M42, Oracle and AstraZeneca Collaborate to Advance AI-Enabled Hypertension Care and Clinical Research in Abu Dhabi
M42, a global health leader powered by artificial intelligence (AI), technology and genomics, Oracle and AstraZeneca today announced a collaboration to explore how AI-enabled digital health infrastructure could help clinicians identify patients with uncontrolled hypertension and support clinical research in Abu Dhabi.
Announced at the Abu Dhabi Future Health Summit 2026, the non-binding initiative builds on the global partnership between AstraZeneca and Oracle, bringing together expertise to explore applications in healthcare in Abu Dhabi. The proposed collaboration will draw on Oracle’s electronic health record, cloud, AI, and clinical workflow capabilities, M42’s healthcare delivery and research expertise in Abu Dhabi, and AstraZeneca’s experience in cardiovascular disease and clinical development.
The partners will initially look at how AI-enabled tools could help care teams identify patients whose blood pressure remains uncontrolled and support guideline-directed care, while helping research teams identify potential participants for clinical trials.
Hypertension impacts an estimated 35% of people in the UAE and is a major risk factor for heart attacks, stroke and kidney disease. By using approved clinical information within existing workflows, the initiative aims to help care teams identify patients who may benefit from further assessment or review of their treatment, supporting earlier, more informed clinical intervention.
In clinical research, the proposed approach would help authorised research teams assess patients who may meet preliminary eligibility criteria for selected studies. Any potential matches would be assessed by qualified professionals. Patient contact or enrolment would follow approved study procedures and documented informed consent.
Dr Ali Anees, Chief Operating Officer, UAE & Bahrain, Global Patient Care at M42, said: “Earlier intervention starts with better intelligence. Through our collaboration with Oracle and AstraZeneca, we aim to explore how responsibly deployed AI and connected clinical information can help identify patients who need further care and support clinical research. Clinical oversight, patient privacy and strong data governance will remain fundamental to this work.”
Iskra Reic, EVP International, AstraZeneca, said: “Creating sustainable healthcare solutions requires collaboration across sectors. By combining the complementary expertise of M42, AstraZeneca and Oracle, this partnership has the potential to strengthen infrastructure, support the adoption of best practices, and enable more connected and efficient approaches to healthcare delivery. Together, we aim to build advanced public health capabilities that deliver lasting value for patients and society.”
Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, said: “Behind every patient living with uncontrolled hypertension is a family looking for answers and relief. Helping people get the care they need, and the opportunity to participate in research that could shape future treatments, has value far beyond any one individual. By extending our partnerships with M42 and AstraZeneca, we aim to combine Oracle’s AI capabilities, clinical workflows, and cloud infrastructure with deep healthcare expertise to help clinicians identify patients who need attention and connect eligible people with research opportunities. That is where technology can make its most meaningful contribution: helping people live healthier lives and strengthening the communities around them.”
The collaboration reinforces Abu Dhabi’s ambition to advance a connected digital health and life sciences ecosystem, bringing together care delivery, health technology, and clinical research. It also reflects the Abu Dhabi Future Health Summit theme, “To Sense is to Predict”, by exploring how information already available to care teams can support earlier identification of risk and more proactive care, with healthcare professionals retaining responsibility for decisions affecting patients.
